Evidence map›Paper›PMID 40595035›Full record

ArticleScientific reports2025

Unraveling chain specific ubiquitination in cells using tandem ubiquitin binding entities.

Muhammad Shahzad Ali, Christopher Rainville, Janelle Pedroza, David E Sterner, Hehe Wang, Kumar Suresh, Tauseef R Butt

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Evolving CRBN ligands enhance the drug-like properties of protein degraders.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad Shahzad AliProgenra Inc, 271A Great Valley Parkway, Malvern, PA, 19335, USA.
Christopher RainvilleProgenra Inc, 271A Great Valley Parkway, Malvern, PA, 19335, USA.
Janelle PedrozaLifeSensors Inc, 271 Great Valley Parkway, Malvern, PA, 19335, USA.
David E SternerProgenra Inc, 271A Great Valley Parkway, Malvern, PA, 19335, USA.
Hehe WangProgenra Inc, 271A Great Valley Parkway, Malvern, PA, 19335, USA.
Kumar SureshProgenra Inc, 271A Great Valley Parkway, Malvern, PA, 19335, USA.
Tauseef R ButtProgenra Inc, 271A Great Valley Parkway, Malvern, PA, 19335, USA. butt@progenra.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polyubiquitination of proteins serves distinct functions that are governed by the nature of polyubiquitin chains built on target proteins. Among the eight distinct type of ubiquitin chains, lysine 48 (K48)-linked chains are specifically associated with proteasomal degradation, while lysine 63 (K63)-linked chains are primarily involved in regulating signal transduction and protein trafficking. The ubiquitin-proteasome system (UPS) has recently been exploited in drug discovery and introduced PROTACs (Proteolysis Targeting Chimeras), or molecular glues (MGs), to hijack ubiquitin E3 ligases, to facilitate the targeted degradation of specific proteins. However, assessment of PROTAC or MG mediated endogenous target protein ubiquitination in a linkage-specific manner in high throughput format remains a challenge. In this study, we applied chain-specific TUBEs (Tandem Ubiquitin Binding Entities) with nanomolar affinities for polyubiquitin chains in HTS assays to investigate the ubiquitination dynamics of RIPK2, a key regulator of inflammatory signaling. Using L18-MDP to induce K63 ubiquitination of RIPK2 and RIPK degrader-2, a RIPK2 PROTAC to induce K48 ubiquitination, we demonstrate that chain-selective TUBEs can differentiate and unravel context dependent linkage specific ubiquitination of endogenous RIPK2. Potential application of this technology to other target proteins and cellular contexts will be discussed.

Indexed as

PolyubiquitinUbiquitinUbiquitinationHEK293 CellsHumansLysineProteasome Endopeptidase ComplexProtein BindingProteolysisUbiquitin-Protein LigasesLysinePolyubiquitinProteasome Endopeptidase ComplexUbiquitinUbiquitin-Protein LigasesE3 ligasesMolecular gluesPROTACsProteasomeTUBEsUbiquitin binding domains

Identifiers

PMID40595035
PMCPMC12217038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.